Pressure BioSciences, Inc.
PBIO · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | 0.00 |
| FCF Yield | -11.42% | -27.48% | -115.95% | -17.40% |
| EV / EBITDA | -10.13 | -12.96 | -8.73 | -18.01 |
| Quality | ||||
| ROIC | 24.04% | 13.47% | 35.40% | 22.98% |
| Gross Margin | 10.49% | 33.20% | -6.78% | -55.56% |
| Cash Conversion Ratio | 0.10 | 0.23 | 0.11 | 0.13 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.17% | -6.20% | -0.41% | 7.06% |
| Free Cash Flow Growth | 62.04% | 78.43% | -1,069.67% | 18.04% |
| Safety | ||||
| Net Debt / EBITDA | -8.36 | -10.37 | -6.58 | -14.66 |
| Interest Coverage | -0.55 | -0.28 | -2.38 | -0.39 |
| Efficiency | ||||
| Inventory Turnover | -777.54 | 0.39 | 1.09 | 1.38 |
| Cash Conversion Cycle | 39.67 | -673.24 | -230.46 | -11.66 |